Lilly and Novo Nordisk’s battle for weight loss drugs reaches pharmacies
Weight loss drug Zepbound gains ground in the US against Novo Nordisk’s Wegovy. Lilly has about 40% market share in the U.S., reaching 130,000 prescriptions in the week ending July 19, compared to Wegovy’s 200,000, according to IQVIA data.
POPULAR POSTS
Poland prepares for peaking floods
September 20, 2024
Italy evacuates thousands as Boris hits the north
September 20, 2024
China and the US race to tame nuclear fusion for clean energy
September 20, 2024
LIVE STREAM